David D. Meek - 17 Jan 2023 Form 4 Insider Report for Mirati Therapeutics, Inc.

Role
Chief Executive Officer, Director
Signature
/s/ Reena R. Desai, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
17 Jan 2023
Net transactions value
-$134,715
Form type
4
Filing time
19 Jan 2023, 08:45:56 UTC
Previous filing
21 Dec 2022
Next filing
24 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Sale $134,715 -3,179 -4.9% $42.38 61,792 17 Jan 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 14, 2022.